By David Tuller, DrPH As I wrote yesterday, Mahana Therapeutics has recently licensed from King’s College London an “innovative digital therapeutic”, a web-based program delivering a course of cognitive behavioral therapy to patients with irritable bowel syndrome. A page on the Mahana site promoting this web-delivered IBS-CBT program furthers the ...

By David Tuller, DrPH Yesterday I sent a freedom-of-information request to King's College London about the recently announced licensing deal it has with Mahana Therapeutics. The deal involves a web-based CBT program for irritable bowel syndrome, which I have written about here and here. This morning I sent a note ...

By David Tuller, DrPH On January 10th, the following information was announced in a press release: Mahana Therapeutics, a digital therapeutics company reimagining the treatment of chronic diseases, today announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and ...

By David Tuller, DrPH Had things gone as planned, the PACE trial should have been able to serve as proof that so-called medically unexplained symptoms (MUS), in this case what the investigators referred to as chronic fatigue syndrome--could be successfully treated with psychological and behavioral therapies. The Lancet published the ...

By David Tuller, DrPH Last October, I gave a talk in Oxford (not AT Oxford) about the dung-heap known as the Lightning Process trial which was published in 2017 in Archives of Disease in Childhood, a BMJ journal. The study's full name: "Clinical and cost-effectiveness of the Lightning Process in addition ...